LD-2 disclosure · 1st Quarter - Report
CLENE NANOMEDICINE
Coverage · No income or expenses were reported on this filing.
Client
- Description
- Biopharmaceutical company focused on neurodegenerative diseases,including ALS
- Location
- Utah · United States of America
Registrant
- Description
- Government Relations Firm
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
1 issueHealth Issues
Issues related to accelerated approval.
LobbyistsBRIAN SUTTER · EMILY ELIZABETH WILKINSON-HOLLAND · mr CHRISTOPHER DAVIS · KIMBERLEE TRZECIAK
Covered position (BRIAN SUTTER): Staff Dir. W&M Health subcommittee, Chairman Dave Camp April'13-Dec'14. Professional Staff, W&M Health subcommittee, Chairman Dave Camp, Jan'11-April'13. Leg Dir. Rep Dave Camp, May'08-Jan'11. Leg Asst Rep Dave Camp, Feb'03-May'08. Staff Ast July'02
Covered position (EMILY ELIZABETH WILKINSON-HOLLAND): Staff -Rep. Price (2010-11), LA: Rep. Grimm (2011-12), Rep. Black (2012-13), Sen.Vitter (2013-2015), Sen. Heller (2015-17), Policy Adv. to the Sec.- Dept of HHS (3/2017-8/2017), Sr Advisor to Administrator - Ctrs for Medicare & Medicaid (8/17- 5/19).
Covered position (mr CHRISTOPHER DAVIS): Staff Assistant, Legislative Assistant, Senior Legislative Assistant, and Legislative Director - Rep. Rick Boucher (2006-2011)
Covered position (KIMBERLEE TRZECIAK): FDA. Dep. Commissioner; 8/23-1/25. Assoc. Commissioner Leg. Affairs; 2/2022-08/2023. House Com. Energy & Commerce: Chief Health Advisor, 2/22-4/19. Sen. Health Policy Advisor, 3/19-3/15. Rep. John D. Dingell - LD, 05/13-07/11. Sen. LA, 7/11-08/09, LA
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS) · Food & Drug Administration (FDA)